Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma

Published:2020-11 Issue:8 Volume:1 Page:100139
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Anagnostou Valsamo,Bruhm Daniel C.,Niknafs Noushin,White James R.,Shao Xiaoshan M.^ORCID,Sidhom John William,Stein Julie,Tsai Hua-Ling,Wang Hao,Belcaid Zineb,Murray Joseph,Balan Archana,Ferreira Leonardo,Ross-Macdonald Petra,Wind-Rotolo Megan,Baras Alexander S.,Taube Janis,Karchin Rachel,Scharpf Robert B.,Grasso Catherine,Ribas Antoni^ORCID,Pardoll Drew M.,Topalian Suzanne L.,Velculescu Victor E.^ORCID

Funder

Bristol-Myers Squibb

US National Institutes of Health

Commonwealth Foundation

Bloomberg-Kimmel Institute for Cancer Immunotherapy

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

V Foundation

Swim Across America

Allegheny Health Network – Johns Hopkins Research Fund

LUNGevity Foundation

Mark Foundation For Cancer Research

Barney Foundation

Moving for Melanoma of Delaware

Laverna Hahn Charitable Trust

Melanoma Research Alliance

Cancer Research Institute–Stand Up 2 Cancer

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference64 articles.

1. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N. Engl. J. Med.,2015

2. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;N. Engl. J. Med.,2019

3. The neoantigen landscape underlying clinical response to ipilimumab;Snyder Charen;J. Clin. Oncol.,2014

4. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma;Liu;Nat. Med.,2019

5. Tumor mutational load predicts survival after immunotherapy across multiple cancer types;Samstein;Nat. Genet.,2019

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumour mutational burden: clinical utility, challenges and emerging improvements;Nature Reviews Clinical Oncology;2024-08-27

2. A novel mitochondria-related algorithm for predicting the survival outcomes and drug sensitivity of patients with lung adenocarcinoma;Frontiers in Molecular Biosciences;2024-08-08

3. Exploiting temporal aspects of cancer immunotherapy;Nature Reviews Cancer;2024-06-17

4. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours;Nature Reviews Cancer;2024-06-12

5. In Situ Synthesis of an Immune-Checkpoint Blocker from Engineered Bacteria Elicits a Potent Antitumor Response;ACS Synthetic Biology;2024-05-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3